Table 2.

Numbers of infections (any type), incidence rates, and incident rate ratios by eGFR categories within 12 mo of follow-up

CharacteristicNo. of Participants with Multiple Infections, % in RowTotal Counts of InfectionsPerson-Years at RiskCrude Incidence Rate per 1000 person-yr (95% CI)Adjusted Incidence Ratea per 1000 person-yr (95% CI)Adjusted Incidence Rate Ratioa (95% CI)
012≥3
Overall (n=1,139,470)1,060,120 (93)61,082 (5.4)12,610 (1.1)5658 (0.5)106,8071,128,31395 (94 to 95)85 (84 to 86)
eGFR, ml/min per 1.73 m2
 ≥105 (n=357,687)335,708 (93.9)17,825 (5)2974 (0.8)1180 (0.3)28,097355,97579 (78 to 80)92 (90 to 94)1.08 (1.03 to 1.14)
 90–104 (n=346,623)327,215 (94.4)15,452 (4.5)2756 (0.8)1200 (0.3)25,362344,80074 (73 to 74)80 (79 to 82)1 (Reference)
 60–89 (n=365,491)338,166 (92.5)20,585 (5.6)4641 (1.3)2099 (0.6)37,394361,369103 (102 to 105)78 (76 to 79)0.93 (0.89 to 0.98)
 30–59 (n=63,805)54,510 (85)6355 (10)1935 (3)1005 (2)13,85061,141227 (223 to 230)106 (102 to 110)1.08 (1.01 to 1.14)
 <30 (n=5864)4521 (77)865 (15)304 (5)174 (3)21045026419 (401 to 436)211 (194 to 229)1.53 (1.39 to 1.69)
  • 95% CI, 95% confidence interval.

  • a The model was adjusted for age, sex, use of immunosuppressive drugs, prior anti-infection drugs (antibiotics, antimycotics, and antivirals), comorbidities (cardiovascular disease, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, liver disease, hemiplegia/paraplegia, cancer, diabetes, and hypertension), and exposure time.